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Introduction: Papillary renal cell carcinoma (PRCC), which represents around 20% of 
renal cell carcinomas, is a heterogeneous disease that includes different tumor types with 
several clinical and molecular phenotypes. Nivolumab, a fully human IgG4 programed cell 
death protein 1 immune checkpoint inhibitor antibody, has shown not only an overall sur-
vival advantage when compared to everolimus but also a relatively good side-effect profile 
among patients with previously treated advanced or metastatic renal cell carcinoma.
Case report: We describe a case of a young man diagnosed with PRCC that achieved 
a durable response to nivolumab despite a temporary suspension of the treatment due 
to a renal function side effect. To the best of our knowledge, it is the first renal failure 
secondary to nivolumab in a metastatic renal cell carcinoma patient.
Concluding remarks: Nivolumab is a promising drug in patients with metastatic PRCC 
and long-term responses can be achieved. In case of acute renal failure secondary to 
this treatment, temporary therapy suspension and a low dose of systemic corticosteroids 
can recover renal function without a negative impact on treatment efficacy.
Keywords: immunotherapy, long-term response, nivolumab, papillary renal cell carcinoma, programed 
death-ligand 1, renal cell carcinoma, sunitinib, vascular normalization
INtRoDUCtIoN
Over the last year, the treatment of advanced or metastatic renal cancer has been changed by the 
approval of several therapies. The results of a randomized, open-label, phase III study (CheckMate 
025) have been recently published, in which nivolumab showed an overall survival advantage when 
compared to everolimus (25.0 vs. 19.6 months, respectively) with a relatively favorable side-effect 
Abbreviations: CT, computed tomography; IFNγ, interferon-γ; MDSCs, myeloid-derived suppressor cells; PD-1, programed 
cell death protein 1; PD-L1, programed cell death ligand 1; PRCC, papillary renal cell carcinoma; STAT3, signal transducer 
and activator of transcription 3; TAMs, tumor-associated macrophages; Th1, T helper 1; Treg, regulatory T; VEGF, vascular 
endothelial growth factor.
FIGURe 1 | Ct scan images demonstrate a decrease in size of surgical site nodules, inferior vena cava tumor thrombus, paraaortic lymph node 
metastasis, and lung nodules after eight and fifteen infusions of nivolumab. (a) Before nivolumab therapy initiation. (B) After eight infusions of nivolumab. 
(C) After fifteen infusions of nivolumab.
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profile (1). One of the inclusion criteria was the presence of any 
clear cell component in the tumor tissue specimen, excluding 
pure papillary renal cell carcinoma (PRCC), which accounts for 
around 20% of renal cell carcinomas. PRCC is a heterogeneous 
disease that includes different tumor types with different clinical 
and molecular phenotypes (2).
Case RepoRt
A 20-year-old man was referred to our department diagnosed 
with recurrent PRCC after a nephrectomy for localized disease. 
He was previously healthy with no personal or family history of 
interest. Prior to resection of tumor recurrence, sunitinib was 
started on the 4/2 schedule (50 mg once/daily for 4 consecutive 
weeks on treatment followed by 2-week-off), continuing with 
the same treatment after surgery. Then, sunitinib was switched 
to the 2/1 schedule (50 mg once/daily for 2 consecutive weeks 
on treatment followed by 1-week-off) for toxicity, but in the end, 
the patient decided to suspend sunitinib due to side effects. Nine 
months after resection, he developed lung and paraaortic lymph 
node metastasis and the disease reappeared in the surgical site 
and the inferior vena cava tumor thrombus increased in size 
(Figure  1A). The patient started second-line treatment with 
nivolumab at 3 mg/kg every 2 weeks. Two weeks after the fifth 
infusion, a creatinine increment (2.5× above baseline level) and 
non-nephrotic range proteinuria were detected in blood and 
FIGURe 2 | Levels of serum creatinine rose 2 weeks after the fifth infusion of nivolumab. Nivolumab therapy was discontinued and immediately prednisone 
treatment was initiated. Serum creatine levels diminished and nivolumab could be restarted.
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urine routine analyses, leading to an acute kidney injury grade 
2 diagnosis. At that moment, after having ruled out obstruction 
and prerenal causes, we discontinued the nivolumab therapy and 
immediately started treatment with prednisone at 1 mg/kg every 
day and 3  days later, when the acute renal failure improved to 
grade 1, we initiated a progressive decrease of the corticosteroids 
dose (Figure 2). Nivolumab was restarted at the same dose 18 days 
after the suspension of prednisone, having been suspended for 
39 days in total, with no worsening of the renal function. After 
eight infusions of nivolumab, a computed tomography (CT) 
scan showed a partial response at thoracic and abdominal levels 
(Figure 1B). At present, the patient continues with the treatment, 
there have been no new immune-related adverse events, and the 
last CT scan has shown a durable partial response (Figure 1C) 
after 15 infusions of treatment.
BaCKGRoUND aND DIsCUssIoN
Little is known about the efficacy of nivolumab in PRCC, and 
only one clinical case of a patient achieving a dramatic response 
has been reported in the literature (3). Here, we report, to our 
knowledge, the second case of a partial response to nivolumab 
achieved in a PRCC patient, with several outstanding features 
that make it noteworthy.
It was recently reported that the expression of programed cell 
death-ligand 1 (PD-L1) in the immune component increased 
with pazopanib therapy, while CD8 expression decreased (4). 
It is unclear if the same happens with sunitinib (5, 6), but it 
may be an explanation to justify the response achieved in our 
case and in the case report by Geynisman. We analyzed PD-L1 
tumor expression by immunohistochemistry and found that 
compared to the pre-sunitinib tumor tissue sample, the number 
of stained tumor cells and stain intensity is higher in the post-
sunitinib tumor tissue sample (Table 1; Figure 3). CheckMate 
025 clinical trial results do not support this hypothesis, because 
the expression of PD-L1 was not predictive of tumor response 
to nivolumab, but the immunohistochemical analysis in archival 
tissue samples obtained before previous regimens of antiangio-
genic therapy probably distorts these results taking into account 
the dynamic and inducible nature of PD-L1 expression (7). On 
the other hand and related to this, there are different ongoing 
clinical trials to test combination therapies of anti-programed 
cell death protein 1 (PD-1) or anti-PD-L1 drugs with antian-
giogenic drugs (8). The rationale for this approach is based on 
FIGURe 3 | Immunohistochemical analysis of pD-L1 expression was 
performed using pD-L1 IHC 22C3 pharmDx (qualitative 
immunohistochemical assay using monoclonal mouse anti-pD-L1, 
clone 22C3). Papillary renal cell carcinoma (hematoxylin and eosin stain; 
original magnification, ×10) (a). Compared to the pre-sunitinib tumor tissue 
sample (B), the number of stained tumor cells and stain intensity is higher in 
the post-sunitinib tumor tissue sample (original magnification, ×20) (C). In the 
pre-treatment tissue sample, the PD-L1 expression is restricted to two foci as 
in the image (B), while in the post-treatment tissue sample, there are multiple 
areas of focal expression. Quantitative PD-L1 expression: 15% (B) vs. 40% 
(C). Two well-experienced pathologists (Ihab Abdulkader and José 
Antúnez-López) examined the immunohistochemical slides in a blinded 
fashion. Only tumor cells with a complete or partial circumferential linear 
plasma membrane staining at any intensity were considered for manual 
quantification.
taBLe 1 | patient characteristics before nivolumab therapy.
Age (years) 23
Gender Male
ECOG PS 1
MSKCC group risk Intermediate
Stage IV
Tumor disease location Surgical site nodules
Paraaortic lymph node
Lung nodules
Inferior vena cava tumor thrombus
Tumor characteristics
Histological subtype Papillary renal cell carcinoma
Fuhrman nuclear grade 3
PD-L1 expression (%)
Pre-sunitinib sample <5%
Post-sunitinib sample 20%
Previous therapies Sunitinib
Previous surgeries Nephrectomy
Tumor recurrence resection
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the fact that targeting the vascular endothelial growth factor 
(VEGF) axis may attenuate tumor-induced immunosuppres-
sion, allowing the tumor to become more responsive to immu-
notherapy. It is well known that the abnormal tumor vasculature 
can impede T effector cell infiltration into tumors and create a 
hypoxic and acidic tumor microenvironment that, among other 
actions, increases the accumulation of regulatory T (Treg) cells 
and myeloid-derived suppressor cells (MDSCs), decreases T cell 
priming, impairs T effector cells, and polarizes tumor-associated 
macrophages (TAMs) to the immune inhibitory M2-like pheno-
type. Moreover, hypoxia can also upregulate multiple immune-
suppressive growth factors and cytokines. Pharmacologically 
induced “vascular normalization” can normalize the tumor 
vasculature and generate a more homogeneous distribution of 
perfused tumor vessels, facilitating the infiltration of T effector 
cells, while reducing MDSCs and Treg cells accumulation. In 
addition, mitigation of hypoxia and acidity by improved vascular 
perfusion polarizes TAMs to an immunostimulatory M1-like 
phenotype (9). Sunitinib, besides promoting these effects, 
blocks the signal transducer and activator of transcription 3 
(STAT3) pathway, which is an immunosuppressive pathway 
favoring differentiation into regulatory cells and tumor growth. 
Decreasing STAT3 signaling diminishes the formation of Tregs 
cells and promotes the formation of effector T helper 1 (Th1) 
cells secreting interferon-γ (IFNγ) (10). In this context, as first 
described by Pardoll (11), the production of IFNγ by T cells 
upon recognition of their cognate antigen results in the reactive 
expression of PD-L1 by tumor cells and in the anergy induction 
in surrounding T cells (adaptive immune resistance).
Long-term follow-up analysis of the patients involved in 
the phase I trial of nivolumab showed that 10 patients (29%) 
achieved objective responses with median response duration 
of 12.9  months (8.4–29.1+  months) (12). In the phase II trial 
of nivolumab, the objective response rate was 21.6% (95% CI 
15.6–28.6), and median response duration was 23 months (80% 
CI 15.7–35.1) (13). In our case, the patient maintains a partial 
response after more than 8  months of starting treatment with 
nivolumab (response duration: 8.07+ months). Despite the fact 
that Geynisman et al. reported a case of a partial response in a 
patient with the same tumor subtype, it is the first case reported 
of a long-term response to nivolumab in a PRCC patient with 
well-defined survival data.
There are 14 cases clearly reported in the literature of renal 
side effects due to monotherapy with anti-PD-1 drugs, 7 of them 
in the metastatic melanoma setting, 6 in the non-small cell lung 
cancer setting, and 1 in the bladder carcinoma setting (14–17). 
Commonly, the clinical course is asymptomatic, with a gradual 
creatinine increment, and most patients improve with the use of 
low dose of corticosteroids. As an added complexity, our patient 
had a single kidney due to prior nephrectomy and, therefore, 
kidney biopsy was discarded then of evaluating the risks and 
benefits (18). Preliminary clinical data seem to show that sys-
temic corticosteroids and other immunosuppressant drugs used 
for immune-related adverse events might not have such a nega-
tive impact on efficacy. A similar time to response and overall 
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response rate was observed in melanoma patients treated with 
nivolumab who received systemic immunosuppressive therapy 
and those who did not (19, 20).
In an experimental animal model of autoimmune kidney 
disease, it is described that macrophage and T cells mediate injury 
and are prominent. Also, it is known that PD-L1 is constitutively 
expressed on kidney tubular epithelial cells and that intrarenal 
expression of PD-1 and its ligands increases in response to 
autoimmune-mediated renal inflammation. As demonstrated 
by Menke et  al. (21) in animal models of autoimmune kidney 
disease, glomerular and tubular damage is greater in PD-L1 
knockout mice compared to wild-type mice.
Taking this into account, we hypothesize that in humans the 
blockade of the PD-1/PD-L1 axis with nivolumab is responsible 
for the disinhibition of different immune cells related to renal 
damage, unbalancing the equilibrium toward a proinflammatory 
state, and, finally, facilitating the development of an acute renal 
impairment.
Brahmer et al. (22) investigated the PD-1 occupancy on cir-
culating T cells over time using flow cytometric analysis. PD-1 
occupancy after one infusion of nivolumab appeared to be dose 
independent, with a mean plateau occupancy of 72% at ≥57 days. 
These data could explain why the effectiveness of treatment does 
not appear to have been compromised in the case of our patient 
despite discontinuation of the treatment for 39 days due to acute 
renal failure grade 2.
CoNCLUDING ReMaRKs
Nivolumab is a promising drug in patients with metastatic PRCC, 
and long-term responses can be achieved. Although few cases 
have been described, the appearance of immune-related adverse 
events can be a problem to solve during anti-PD-1 therapies. To 
improve its management and to clarify the peculiarities in the 
pathogenesis of acute renal failure induced by anti-PD-1 drugs, 
further clinical and translational trials must be developed. In 
case of acute renal failure secondary to this treatment, temporary 
therapy suspension and a low dose of systemic corticosteroids can 
recover renal function without a negative impact on treatment 
efficacy.
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